Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
MID1 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | O15344 |
| Other Accession | NP_001092094.1, NP_001180206.1, NP_000372.1, NP_001180207.1 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 75251 Da |
| Antigen Region | 575-603 aa |
| Gene ID | 4281 |
|---|---|
| Other Names | E3 ubiquitin-protein ligase Midline-1, 632-, Midin, Putative transcription factor XPRF, RING finger protein 59, RING finger protein Midline-1, Tripartite motif-containing protein 18, MID1, FXY, RNF59, TRIM18, XPRF |
| Target/Specificity | This MID1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 575-603 amino acids from the C-terminal region of human MID1. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | MID1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | MID1 |
|---|---|
| Synonyms | FXY, RNF59, TRIM18, XPRF |
| Function | Has E3 ubiquitin ligase activity towards IGBP1, promoting its monoubiquitination, which results in deprotection of the catalytic subunit of protein phosphatase PP2A, and its subsequent degradation by polyubiquitination. |
| Cellular Location | Cytoplasm. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, spindle. Note=Microtubule- associated. It is associated with microtubules throughout the cell cycle, co-localizing with cytoplasmic fibers in interphase and with the mitotic spindle and midbodies during mitosis and cytokinesis |
| Tissue Location | In the fetus, highest expression found in kidney, followed by brain and lung. Expressed at low levels in fetal liver. In the adult, most abundant in heart, placenta and brain |
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of the tripartite motif (TRIM) family, also known as the 'RING-B box-coiled coil' (RBCC) subgroup of RING finger proteins. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This protein forms homodimers which associate with microtubules in the cytoplasm. The protein is likely involved in the formation of multiprotein structures acting as anchor points to microtubules. Mutations in this gene have been associated with the X-linked form of Opitz syndrome, which is characterized by midline abnormalities such as cleft lip, laryngeal cleft, heart defects, hypospadias, and agenesis of the corpus callosum. This gene was also the first example of a gene subject to X inactivation in human while escaping it in mouse. Multiple different transcript variants are generated by alternate splicing; however, the full-length nature of some of the variants has not been determined.
References
Need, A.C., et al. Hum. Mol. Genet. 18(23):4650-4661(2009)
Treutlein, J., et al. Arch. Gen. Psychiatry 66(7):773-784(2009)
Styrkarsdottir, U., et al. Nat. Genet. 41(1):15-17(2009)
Scapoli, L., et al. Eur. J. Oral Sci. 116(6):507-511(2008)
Aranda-Orgilles, B., et al. PLoS ONE 3 (10), E3507 (2008) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
